(68Ga)PSMA-HBED-CC for Prostate Cancer

Phase-Based Progress Estimates
Holden Comprehensive Cancer Center, Iowa City, IAProstate Cancer(68Ga)PSMA-HBED-CC - Drug
What conditions do you have?

Study Summary

This trial is looking at a new radiotracer, Ga-68 PSMA-HBED-CC, to see if it can detect metastatic prostate cancer early. Investigators will use a test and re-test design to see how well the radiotracer works.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 60 minutes post-injection

60 minutes post-injection
Biodistribution assessment
Day 15
Reproducibility assessment

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: (68Ga)PSMA-HBED-CC · No Placebo Group · Phase < 1

Experimental Group · 1 Intervention: (68Ga)PSMA-HBED-CC · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 60 minutes post-injection

Who is running the clinical trial?

Janet PollardLead Sponsor
Janet Pollard, M.D.Principal InvestigatorUniversity of Iowa

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are male.
You may or may not be receiving hormone, chemotherapy, or radium therapy.

Frequently Asked Questions

How many participants are being considered for inclusion in this clinical research?

"Sign-ups for this particular research project have been closed. First published on July 14th 2016 and last edited on January 29th 2021, other trials may be more suitable if you are seeking to participate in a clinical study. Currently, 1252 studies related to prostate cancer and 17 (68Ga)PSMA-HBED-CC trials are actively recruiting patients." - Anonymous Online Contributor

Unverified Answer

Are there any opportunities for patients to participate in this clinical investigation currently?

"Unfortunatley, the recruitment period for this clinical trial has concluded. It first went up on July 14th 2016 and was last edited on January 29th 2021. If you are looking to join another study there are currently 1252 trials seeking participants with prostate cancer and 17 studies that require (68Ga)PSMA-HBED-CC patients." - Anonymous Online Contributor

Unverified Answer

What medical issues does (68Ga)PSMA-HBED-CC typically address?

"(68Ga)PSMA-HBED-CC has been approved for treating prostate cancer and is also effective in managing skin disorders such as eczema, dyshidrotic, psoriasis, and neurodermatitis." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.